NCT07533006Phase 2Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
In the register
The register attaches this trial to LY4005130 (Eli Lilly), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Eli Lilly and Company
- Participants (registry)
- 60
- Start
- April 2026
- Primary completion
- June 2027 (planned)
- Study completion
- October 2027 (planned)
- Last registry update
- September 2026
- Countries
- United States, Canada, China, Netherlands, Poland, South Korea, United Kingdom
Conditions studied: Alopecia Areata
Interventions: LY4005130, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.